On the effect of biochemotherapy in metastatic malignant melanoma: An immunopathological evaluation

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 401-407

  Håkansson, Annika ^a   Håkansson, Leif ^a   Gustafsson, Bertil ^a   Krysander, Lennart ^a   Rettrup, Björn ^b   Ruiter, Dirk ^c   Bernsen, Monique R ^a,c  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biochemotherapy; Histopathology; Immunotherapy; Metastatic melanoma; Neo adjuvant treatment; Prediction; Regressive changes

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CISPLATIN; DACARBAZINE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CD4 LYMPHOCYTE COUNT; CISPLATIN; DACARBAZINE; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 17144453402     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00010     Document Type: Article

References (34)

1. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alfa and chemotherapy. Semin Oncol 1997; 24 (suppl 4):S39-S43.
2. Khayat D, Borel C, Tourani JM, Benhammouda A, Antonie E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic malignant melanoma. J Clin Oncol 1993; 11:2173-2180.
3. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.
4. Proebstle TM, Fuchs T, Scheibenbogen C, Sterry W, Keilholz U. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res 1998; 8:557-563.
5. Richards JM, Gale D, Metha N, Lestingi T. Combination chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17:651-657.
6. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon-alpha2b. J Clin Oncol 1999; 17:968-975.
7. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86 (2):179-184.
8. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomised trial. J Clin Oncol 2002; 20 (8):2045-2052.
9. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66:249-254.
10. Hurwitz PJ. Spontaneous regression of metastatic malignant melanoma. Ann Plast Surg 1991; 26:403-406.
11. Abershold P, Hyatt C Johnson S, Hines K, Korcak L, Sanders M, et al. Lysis of autologous melanoma cells by tumour-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991; 83:932-937.
12. von Depka Prondzinski M, von Stamm U, Bröcker EB. Heterogeneity of the T-cell and macrophage infiltrate in cutaneous and subcutaneous metastases of melanoma patients. Melanoma Research 1993; 3:203-208.
13. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81:1893-1904.
14. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
15. Mihm MC, Clemente CG, Cascinelli N. Tumour-infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-47.
16. Håkansson A, Gustafsson B, Krysander L, Håkansson L. Effect of interferon-α on tumour-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 1998; 18:33-39.
17. Håkansson A, Gustafsson B, Krysander L, Håkansson L, Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon-alpha treatment. Br J Cancer 1996; 74:670-676.
18. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 2001; 85 (12):1871-1877.
19. Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, et al. Tumour metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 1999; 31:116-122.
20. Fritsch M, Rosenberg SA, Duray PH. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. J Immunother 2000; 23 (5):557-569.
21. Mc Govern VJ. Spontaneous regression of melanoma. Pathology 1975; 7:91-99.
22. Kang S, Barnhill RL, Mihm MC, Sober AJ. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 1993; 20:126-129.
23. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. Virchows Arch A Pathol Anat Histopathol 1985; 408:241-247.
24. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123:1326-1330.
25. Pehamberger H, Soyer P, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16:1425-1429.
26. Grob JJ, Dreno B, Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351:1905-1910.
27. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup Trial E1690/S9111/C9190. J Clin Oncol 2000; 18 (12):2444-2458.
28. Kirkwood JM, Hunt Strawderman M, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1648. J Clin Oncol 1996; 14:7-17.
29. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19 (9):2370-2380.
30. von Stamm U, Bröcker EB, von Depka Prondzinski M, Ruiter DJ, Rümke P, Broding C, et al. Effects of systemic interferon-α (IFN-α) on the antigenic phenotype of melanoma metastases. EORTC Melanoma Group Cooperative study no. 18852. Melanoma Res 1993; 3:173-180.
31. Mizutani Y, Yoshida O, Bonavida B. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diaminedichloroplatinum. J Urol 1998; 160:561-570.
32. Arenberg DA, Kunkel SL, Burdick MD, Standiford TJ, Strieter RM. Regulation of monocyte derived interleukin 1 receptor antagonists by cisplatinum. Cytokine 1995; 7:89-96.
33. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L. On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother 1999; 48:253-262.
34. Håkansson A, Gustafsson B, Krysander L, Rettrup B, Håkansson L, Ruiter D, et al. Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28. Cancer Immunol Immunother 2002; 51:499-504.